Mechanism Overview: The Prostaglandin-Hair Connection
The connection between prostaglandins and hair growth was discovered serendipitously through the development of bimatoprost (Latisse/Lumigan) for eyelash growth. Bimatoprost is a prostaglandin F2α (PGF2α) analog originally developed as an eye drop for glaucoma, where patients noticed the striking side effect of longer, darker, and thicker eyelashes. This observation led to FDA approval of bimatoprost 0.03% for hypotrichosis of the eyelashes (Latisse, 2008) and sparked intense interest in whether prostaglandin analogs could be used for scalp hair loss. The prostaglandin family includes both hair-promoting (PGF2α, PGE2) and hair-inhibiting (PGD2) members, and the balance between these opposing signals may be a critical determinant of hair growth or loss.
Detailed Mechanism: Prostaglandin Synthesis and Receptor Signaling
Prostaglandins are lipid signaling molecules derived from arachidonic acid through the cyclooxygenase (COX) pathway. Arachidonic acid is released from membrane phospholipids by phospholipase A2 and converted to prostaglandin H2 (PGH2) by COX-1 or COX-2. PGH2 is then converted to specific prostaglandins by terminal synthases: PGD synthase produces PGD2, PGE synthase produces PGE2, and PGF synthase produces PGF2α.
PGF2α signals through the FP receptor (PTGFR), a G-protein coupled receptor that activates phospholipase C, increasing intracellular calcium and activating protein kinase C. In the hair follicle, FP receptor activation promotes anagen by stimulating keratinocyte proliferation and inhibiting apoptosis. Bimatoprost, as a PGF2α analog, activates the FP receptor and also has activity at the prostamide receptor (a distinct but related pathway).
PGE2 signals through four receptors (EP1-4), with EP3 and EP4 being the most relevant for hair. EP4 activation promotes anagen through cAMP/PKA signaling. A study by Nelson et al. (2013), published in the Journal of Investigative Dermatology, demonstrated that PGE2 promotes hair growth in mouse models and that PGE2 levels are reduced in balding scalp.
PGD2 signals through the DP1 and DP2 (CRTH2) receptors. PGD2 is the most potent hair growth inhibitor among the prostaglandins. A landmark study by Garza et al. (2012), published in Science Translational Medicine, demonstrated that PGD2 levels were significantly elevated in balding scalp compared to non-balding scalp (by approximately 3-fold), and that PGD2 inhibited hair growth in both mouse and human hair follicle cultures. Treatment with a DP2 antagonist partially restored hair growth in the PGD2-treated follicles, confirming that PGD2’s inhibitory effect is mediated through the DP2 receptor.
Detailed Mechanism: The PGD2-PGF2α Balance in AGA
The Garza et al. (2012) study was notable because it identified a specific molecular signal (PGD2) that is elevated in balding scalp and actively inhibits hair growth. The study also found that the enzyme that produces PGD2 (PGD2 synthase, PTGDS) was upregulated in balding scalp, while the enzyme that produces PGE2 (microsomal PGE synthase-1, PTGES) was downregulated. This suggests that AGA involves a shift in the prostaglandin balance from hair-promoting (PGE2, PGF2α) to hair-inhibiting (PGD2)—a shift that is driven by the upregulation of PTGDS and downregulation of PTGES.
The mechanism by which androgens shift the prostaglandin balance has been partially characterized. DHT has been shown to upregulate PTGDS expression in dermal papilla cells, increasing PGD2 production. Simultaneously, DHT may downregulate PTGES, reducing PGE2 production. The net effect is an accumulation of PGD2 in the perifollicular environment, which inhibits hair growth through DP2 receptor activation on follicle keratinocytes.
PGD2’s mechanism of hair growth inhibition involves DP2 receptor-mediated activation of the Gαi pathway, which reduces intracellular cAMP—a signaling molecule that promotes keratinocyte proliferation (the opposite of caffeine’s PDE-inhibiting, cAMP-increasing mechanism discussed in our caffeine article). PGD2 also promotes the transition from anagen to catagen through mechanisms that may involve TGF-β1 upregulation.
Research Evidence: Clinical Trials of Prostaglandin Analogs for Scalp
Despite the strong preclinical evidence, clinical trials of prostaglandin analogs for scalp hair loss have been disappointing. A Phase 2 trial of bimatoprost 0.03% solution applied to the scalp for AGA was conducted by Allergan but did not achieve its primary endpoint. The results were never published in a peer-reviewed journal, but company communications indicated that the effect size was too small to justify further development. The reasons for the failure may include: (1) the concentration or formulation was insufficient for scalp penetration (scalp skin is thicker than eyelid skin); (2) bimatoprost’s effect on scalp follicles differs from its effect on eyelash follicles; (3) the prostaglandin pathway is only one of several mechanisms driving AGA, and addressing it alone is insufficient.
Latancoprost (Xalatan), another PGF2α analog, has also been studied for scalp hair loss. A study by Blum et al. (2015) examined topical latanoprost 0.1% for AGA in a small pilot study and reported modest improvement in hair count, but the study was uncontrolled and the results have not been confirmed in larger trials.
DP2 antagonists (blocking the hair-inhibiting PGD2 receptor) represent a complementary approach. Setipiprant, a DP2 antagonist, was studied for AGA in a Phase 2 trial by Allergan. The trial was completed but the results have not been published, and the development program does not appear to have progressed to Phase 3. The lack of published results suggests that the effect was either negative or too modest to be clinically meaningful.
Limitations and Critical Assessment
The prostaglandin-hair story illustrates the challenge of translating findings from one follicle type (eyelash) to another (scalp). Eyelash follicles and scalp follicles differ in their cycle duration, androgen sensitivity, prostaglandin receptor expression, and response to pharmacological manipulation. The success of bimatoprost for eyelashes may not be replicable for scalp hair because the prostaglandin balance shift (elevated PGD2) is specific to AGA-affected scalp and does not occur in eyelashes.
Second, the prostaglandin pathway is one of several mechanisms contributing to AGA, and addressing it alone may be insufficient in the context of ongoing androgen-mediated miniaturization. A more effective approach might combine prostaglandin modulation with anti-androgen therapy. Third, prostaglandin analogs can cause side effects including ocular irritation, skin darkening (hyperpigmentation), and periocular fat atrophy (sunken eye appearance with prolonged use of prostaglandin eye drops). These safety concerns must be carefully evaluated for any scalp application.
Frequently Asked Questions
Can I use Latisse on my scalp? No. Latisse is formulated and FDA-approved for eyelash use only. Applying it to the scalp would be off-label, and the concentration and formulation may not be appropriate for scalp penetration.
Why did bimatoprost work for eyelashes but not scalp? Eyelash and scalp follicles are biologically different. Eyelash follicles are not androgen-sensitive, do not have the PGD2 elevation seen in AGA, and may respond more dramatically to PGF2α analog stimulation. Scalp follicles in AGA have multiple pathological mechanisms that a single prostaglandin analog cannot address.
Will PGD2 inhibitors be available for hair loss? The setipiprant trial did not lead to further development, and no DP2 antagonist is currently in clinical development for hair loss. The prostaglandin pathway remains an interesting target, but the clinical translation has been challenging.
Conclusion
The prostaglandin pathway represents a fascinating aspect of hair follicle biology, with opposing effects of hair-promoting (PGF2α, PGE2) and hair-inhibiting (PGD2) prostaglandins. The Garza et al. (2012) discovery that PGD2 is elevated 3-fold in balding scalp and actively inhibits hair growth identified a novel mechanism contributing to AGA. However, clinical translation has been disappointing: bimatoprost and latanoprost have not demonstrated meaningful efficacy for scalp hair loss, and the DP2 antagonist setipiprant has not progressed beyond Phase 2. The discrepancy between the strong eyelash response and the lack of scalp response may reflect fundamental biological differences between follicle types, the multifactorial nature of AGA (which cannot be addressed by modulating a single pathway), and challenges with scalp penetration of topical formulations. The prostaglandin pathway remains an interesting area of research, but patients should not expect currently available prostaglandin products to improve scalp hair growth.